Burrage Capital Management
Latest statistics and disclosures from Burrage Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Amr, and represent % of Burrage Capital Management's stock portfolio.
- Added to shares of these 1 stock: Amr.
- Started 1 new stock position in Amr.
- Reduced shares in these 10 stocks: , NTLA (-$10M), Epizyme (-$7.0M), EPIX (-$6.8M), NEO (-$6.7M), , CRNX (-$5.6M), CYTK, , HRMY.
- Sold out of its positions in FOLD, AVRO, BCRX, BDTX, CRNX, CYTK, Epizyme, EPIX, G1 Therapeutics, GERN. HRMY, INZY, NTLA, Mei Pharma, MIRM, NEO, RVMD, Turning Point Therapeutics I, Verastem, Y Mabs Therapeutics, ADCT, MRUS.
- Burrage Capital Management was a net seller of stock by $-100M.
- Central Index Key (CIK): 0001796461
Tip: Access up to 7 years of quarterly data
Positions held by Burrage Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Burrage Capital Management
Burrage Capital Management holds 1 positions in its portfolio as reported in the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| 0 0 | 0.0 | $0 | NEW | 0 | 0.00 |
|
Past Filings by Burrage Capital Management
SEC 13F filings are viewable for Burrage Capital Management going back to 2019
- Burrage Capital Management 2021 Q3 filed Nov. 15, 2021
- Burrage Capital Management 2021 Q2 filed Aug. 16, 2021
- Burrage Capital Management 2021 Q1 filed May 17, 2021
- Burrage Capital Management 2020 Q4 filed Feb. 12, 2021
- Burrage Capital Management 2020 Q3 filed Nov. 13, 2020
- Burrage Capital Management 2020 Q2 filed Aug. 14, 2020
- Burrage Capital Management 2020 Q1 filed May 14, 2020
- Burrage Capital Management 2019 Q4 filed Feb. 14, 2020